- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 17.07. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 26.06. | Prenetics Global Limited: World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics' IM8 Health as Global Ambassador and Shareholder | 2 | GlobeNewswire (USA) | ||
| 23.06. | Prenetics stock steady as Cantor reiterates rating on divestiture news | 1 | Investing.com | ||
| 23.06. | Prenetics-Aktie stabil: Cantor bekräftigt Bewertung nach Veräußerungsnachricht | 1 | Investing.com Deutsch | ||
| 20.06. | Bitcoin im Gesundheitssektor: Prenetics wagt mutigen Schritt in neue Märkte | 4 | Coin-Update.de | ||
| 18.06. | Bitcoin-Wette: Gesundheitsunternehmen Prenetics investiert $20M, nachdem die Marktkapitalisierung um 94% gesunken ist | 3 | Bitcoin.com News | ||
| 18.06. | Prenetics becomes first healthcare firm to acquire bitcoin for treasury | 1 | Investing.com | ||
| 18.06. | Prenetics Acquires $20 Million In Bitcoin To Boost Healthcare Bitcoin Treasury Strategy | 1 | Benzinga.com | ||
| 18.06. | Prenetics Global Limited: Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board | 2 | GlobeNewswire (USA) | ||
| 18.06. | Prenetics Global divests ACT Genomics for $46M | 1 | Seeking Alpha | ||
| 18.06. | Prenetics to sell ACT Genomics stake to Delta Electronics for $46 million | 1 | Investing.com | ||
| 18.06. | Prenetics Global Limited: Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction | 1 | GlobeNewswire (USA) | ||
| 16.06. | Cantor Fitzgerald raises Prenetics price target on strong quarterly results | 1 | Investing.com | ||
| 13.06. | Prenetics stock price target raised to $14 from $13 at Cantor Fitzgerald | 1 | Investing.com | ||
| 12.06. | Kursziel für Prenetics-Aktie nach starken Q1-Ergebnissen auf 14 US-Dollar angehoben | 1 | Investing.com Deutsch | ||
| 12.06. | Prenetics stock price target raised to $14 on strong Q1 results | 1 | Investing.com | ||
| 12.06. | Prenetics Global veröffentlicht Finanzergebnisse für Q1 2025 | 1 | Investing.com Deutsch | ||
| 12.06. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.05. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.05. | Prenetics Global Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANSINO BIOLOGICS | 5,140 | -1,25 % | CanSino Biologics Inc: CanSinoBIO Launches its Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health | HONG KONG, June 20, 2025 - (ACN Newswire) - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single... ► Artikel lesen | |
| SINO BIOPHARM | 0,821 | -0,41 % | Minimales Kursplus bei der Sino Biopharmaceutical-Aktie (0,773 €) | Am Aktienmarkt ist das Wertpapier von Sino Biopharmaceutical zur Stunde unauffällig. Der jüngste Kurs betrug 0,77 Euro. Kaum auffällig ist derzeit an der Börse der Kurs von Sino Biopharmaceutical. Das... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 2,085 | +2,46 % | GenScript Biotech Corporation Reports FY 2024 Results | Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth.
PISCATAWAY, N.J., March 12, 2025 /PRNewswire/... ► Artikel lesen | |
| QUANTUM-SI | 1,635 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| INNOVENT BIOLOGICS | 11,100 | +0,91 % | Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that... ► Artikel lesen | |
| SCILEX | 16,160 | 0,00 % | Scilex Holding Co - 8-K, Current Report | ||
| ORIGIN AGRITECH | 0,840 | 0,00 % | Origin Agritech Limited: Origin Agritech Announced Financial Results for the Six Months Ended March 31, 2025 | BEIJING, June 26, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today... ► Artikel lesen | |
| AKESO | 17,300 | +1,76 % | Akeso, Inc.: NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer | HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration... ► Artikel lesen | |
| QIAGEN | 44,285 | +0,72 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EVOTEC | 7,400 | -0,54 % | Evotec, Gerresheimer, Hugo Boss, Puma, Renk Group, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,140 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 35,950 | +4,02 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 7,590 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,950 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| SOLID BIOSCIENCES | 7,070 | 0,00 % | Solid Biosciences gets FDA fast track status for heart disease therapy |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,055 Euro und damit -0,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.